Introduction {#S1}
============

*Escherichia coli* is commonly isolated from clinical bloodstream infections. It is referred to as extraintestinal pathogenic *E. coli* ([@B14]) and is usually multidrug-resistant, potentially leading to sepsis and even death of infected patients ([@B25]). Antibiotic selection as a result of the extensive clinical application of broad-spectrum antibiotics, especially third-generation cephalosporins, has led to the generation of drug-resistant bacteria ([@B3]). Bloodstream infection by multidrug-resistant *E. coli* thus presents difficulties in clinical treatment and has become an important public health problem ([@B4]). The main resistance mechanism of Gram-negative bacteria such as *E. coli* involves the production of a variety of hydrolytically active beta-lactamases, from broad- to extended-spectrum enzymes, and the enzymatic hydrolysis profile and host range are constantly changing from chromosome-mediated to plasmid-mediated AmpC beta-lactamases ([@B11]; [@B20]).

The major beta-lactamase resistance genes in *E. coli* are currently members of the *bla*~CTX--M~ and *bla*~TEM~ groups, which have been reported in many different countries ([@B1]). *bla*~TEM~ were the first beta-lactamase genes found in Gram-negative bacteria. They are specifically transferred by plasmids, and more than 200 subtypes have been identified, mainly encoding enzymes that hydrolyze penicillin and first generation cephalosporins ([@B17]; [@B21]; [@B8]). In contrast, *bla*~CTX--M~-encoded enzymes mainly hydrolyze third generation cephalosporins, are mostly located on plasmids of 40--200 kb ([@B31]), and belong to a wide variety of incompatibility (Inc.) groups. Conjugative plasmids can shuttle between bacteria of the same or different species, thus spreading resistance phenotypes and potentially causing large-scale outbreaks and the prevalence of resistant bacteria. The *bla*~CTX--M~ group beta lactamases have been widely reported to cause bacterial resistance by conjugative plasmids, though the *bla*~CTX~-~M~ group, other *ampC* beta-lactamase resistance genes, such as *bla*~ADC~ and *bla*~CMY~, are also gradually increasing in clinical strains, resulting in greater cephalosporin resistance ([@B15]). Ceftazidine is the main third generation cephalosporin used in Europe, while cefotaxime and cefoperazone are the most extensively used in China ([@B16]). Bacteria with different beta-lactamase genotypes express enzymes with different physical and chemical properties and differences in drug resistance ([@B17]). Importantly, genotype prevalence also differ among regions. However, the characterization of beta-lactamases in bloodstream-infection *E. coli* from elderly patients in China has not yet been reported, and whether the upstream and downstream surroundings of these genes in bloodstream-infection *E. coli* are consistent with other species of bacteria, or if they have special transfer and transmission capabilities, remains unknown. In this study, we carried out phenotypic and genotypic analyses of bloodstream-infection *E. coli* in a tertiary hospital in China to elucidate the genetic environment in selected isolates in relation to different beta-lactamase types on plasmids in different incompatibility groups. This analysis of the genetic context of the beta-lactamase genes may help to clarify their acquisition, with regard to their origin and further dissemination.

Materials and Methods {#S2}
=====================

Bacterial Strains {#S2.SS1}
-----------------

A total of 1242 *E. coli* isolates were recovered from patient samples at Shanghai Sixth People's Hospital South Campus, China, during 2015--2018. Among these, 50 strains of bloodstream-infection *E. coli* were isolated from elderly patients and further characterized with regard to extended-spectrum beta-lactamase (ESBL) and *ampC* genes. *E. coli* ATCC25922, J53, and *E. coli* DH5α were maintained in our laboratory.

Antimicrobial Susceptibility Testing {#S2.SS2}
------------------------------------

Antibiotic susceptibility was determined by disk diffusion or broth dilution, using *E. coli* ATCC25922 as a control strain. The tested antibiotics included: amikacin, gentamicin, tobramycin, trimethoprim/sulfamethoxazole, chloramphenicol, meropenem, imipenem, ciprofloxacin, levofloxacin, ampicillin, aztreonam, cefepime, cefotaxime, ceftazidime, cefazolin, ceftriaxone, and cefoxitin. The results were interpreted in accordance with the guidelines of the Clinical and Laboratory Standards Institute ([@B10]).

Phenotypic Characterization {#S2.SS3}
---------------------------

ESBL production was determined by double-disc synergy tests and confirmed by E-testing, using cefotaxime-cefotaxime-clavulanic acid and ceftazidime-ceftazidime-clavulanic acid strips, according to the CLSI guidelines. Similarly, phenotypic confirmation of plasmid-mediated AmpC production was performed using the AmpC assay *E*-test with cefotetan-ceftatan-clozacillin strips, according to the manufacturer's instructions (BioMerieux, France).

Characterization of Beta-Lactamase Genes {#S2.SS4}
----------------------------------------

The beta-lactamase genotype of each isolate was determined by polymerase chain reaction (PCR) amplification with specific primers for *bla*~TEM~, *bla*~SHV~, *bla*~CTX--M--1~, *bla*~CTX--M--2~, *bla*~CTX--M--8~, *bla*~CTX--M--9~, *bla*~CTX--M--25~, *bla*~OXA--1,~ *bla*~PER~, *bla*~SME~, *bla*~KPC~, *bla*~VIM~, *bla*~NDM~, *bla*~IMP~, *bla*~GES~, *bla*~VEB~, *bla*~DHA~, *bla*~ADC~, *bla*~ACC~, *bla*~CIT~, and *bla*~EBC~, with bacterially isolated DNA as an amplification template. The total volume of the PCR amplification system was 20 μL, containing 1 μL of genomic DNA template (\>50 ng/μL), 10 μL of Premix-rTaq PCR solution (TaKaRa, Japan), 0.4 μL of each primer (10 pmol), and 7 μL of distilled water. PCR was performed using a ProFlex Base Thermal Cycler (Applied Biosystems, Thermo Fisher Scientific, Singapore). The template was denatured at 94°C for 4 min, followed by 35 cycles of 94°C for 40 s, 55°C for 40 s, and 72°C for 40 s, with a final extension stage at 72°C for 5 min. The PCR product was verified by agarose gel electrophoresis and sequencing. All beta-lactamase gene sequencing results were aligned using the BLAST program^[1](#footnote1){ref-type="fn"}^.

Conjugation Experiments {#S2.SS5}
-----------------------

Conjugation experiments were performed using sodium azide-resistant *E. coli* J53 as a receptor. Transconjugants were selected on Luria-Bertani agar plates supplemented with sodium azide (200 μg/mL) (Sigma, Germany) and ampicillin (100 μg/mL). J53 and donor bacteria were resuscitated overnight, and a single colony was selected and enriched for 18 h in LB liquid medium without antibiotics. J53 and donor bacteria were mixed 1:4, and a 0.22 μm pore size filter was applied to the blood plate. Thereafter, 150 μL of the mixed bacteria solution was taken up and added to the filter membrane, and cultured overnight. The filter with the bacteria was then removed and washed in LB liquid medium, diluting 1:100 and 150 μL was then applied to the double-antibody plate, cultured overnight, and a single colony was picked for further experiments. The presence of the beta-lactamase gene in the transconjugant was examined using the primers given in [Table 1](#T1){ref-type="table"}, and the susceptibility of the strain was tested experimentally, as described above.

###### 

Primers used for PCR amplification.

  **Primer**   **Primer sequence (5′--3′)**   **References**
  ------------ ------------------------------ ----------------
  TEMF         TCGGGGAAATGTGCG                [@B26]
  TEMR         TGCTTAATCAGTGAGGCACC           [@B26]
  SHVF         GCCTTTATCGGCCTTCACTCAAG        [@B26]
  SHVR         TTAGCGTTGCCAGTGCTCGATCA        [@B26]
  PRE-F        GCTCCGATAATGAAAGCGT            [@B7]
  PRE-R        TTCGGCTTGACTCGGCTGA            [@B7]
  SME-F        GAGGAAGACTTTGATGGGAGGAT        [@B7]
  SME-R        TCCCCTCAGGACCGCCAAG            [@B7]
  CTX-M-1F     CAGAGATTTTGCCGTCTAAG           [@B28]
  CTX-M-1R     GGCCCATGGTTAAAAAATCACTGC       [@B28]
  CTX-M-2F     CTCAGAGCATTCGCCGCTCA           [@B28]
  CTX-M-2R     CCGCCGCAGCCAGAATATCC           [@B28]
  CTX-M-8F     ACTTCAGCCACACGGATTCA           [@B28]
  CTX-M-8R     CGAGTACGTCACGACGACTT           [@B28]
  CTX-M-9F     GTTACAGCCCTTCGGCGATGATTC       [@B28]
  CTX-M-9R     GCGCATGGTGACAAAGAGAGTGCAA      [@B28]
  CTX-M-25F    GCACGATGACATTCGGG              [@B28]
  CTX-M-25R    AACCCACGATGTGGGTAGC            [@B28]
  OXA-1-F      GGCACCAGATTCAACTTTCAAG         [@B7]
  OXA-1-R      GACCCCAAGTTTCCTGTAAGTG         [@B7]
  ADC-F        GGTATGGCTGTGGGTGTTATTC         This study
  ADC-R        CTAAGACTTGGTCGAAAGGT           This study
  KPC-F        CGTCTAGTTCTGCTGTCTTG           This study
  KPC-R        CTTGTCATCCTTGTTAGGCG           This study
  NDM-F        GGTTTGGCGATCTGGTTTTC           This study
  NDM-R        CGGAATGGCTCACGATC              This study
  IMP-F        GGAATAGAGTGGCTTAAYTCTC         This study
  IMP-R        GGTTTAAYAAAACAACCACC           This study
  VIM-F        GATGGTGTTTGGTCGCATA            This study
  VIM-R        CGAATGCGCAGCACCAG              This study
  VEB-F        GCGGTAATTTAACCAGA              This study
  VEB-R        GCCTATGAGCCAGTGTT              This study
  GES-F        GTTTTGCAATGTGCTCAACG           This study
  GES-R        TGCCATAGCCAATAGGCGTAG          This study
  DHA-F        AACTTTCACAGGTGTGCTGGGT         This study
  DHA-R        CCGTACGCATACTGGCTTTGC          This study
  EBC-F        TCGGTAAAGCCGATGTTGCGG          This study
  EBC-R        CTTCCACTGCGGCTGCCAGTT          This study
  ACC-F        AACAGCCTCAGCAGCCGGTTA          This study
  ACC-R        TTCGCCGCAATCATCCCTAGC          This study
  CIT-F        TGGCCAGAACTGACAGGCAAA          This study
  CIT-R        TTTCTCCTGAACGTGGCTGGC          This study
  chuA-F       GACGAACCAACGGTCAGGAT           [@B9]
  chuA-R       TGCCGCCAGTACCAAAGACA           [@B9]
  yhaA-F       TGAAGTGTCAGGAGACGCTG           [@B9]
  yhaA-R       ATGGAGAATGCGTTCCTCAAC          [@B9]
  TspE4.C2-F   GAGTAATGTCGGGGCATTCA           [@B9]
  TspE4.C2-R   CGCGCCAACAAAGTATTACG           [@B9]
  IS26-F       TTACATTTCAAAAACTCTGCTTACC      This study
  ISEcp1-F     CAAAATGATCCCCTCGTCAAC          This study
  IS903-R      GTTTAATGACCAGCACAGT            This study
  ORF477-R     TCGTTTCGTGGTGCTGAATTT          This study
  blc-R        TTTAGGTAACGCACGTTGGA           This study
  sug-R        GGGCTGTTCTCCTGAATGAT           This study
  ISAba1-F     TGGCACTTGCTTAATAAACGTGG        This study
  tnpA-F       CATCACCGCGATAAAGCACC           This study
  tnpA-R       GGCTCAAAGGCAATACGACC           This study
  M9R-F        GAATTGCCTCCTAGTACGCTTAA        This study
  M9R-R        CGGTTACGTAAGCTAGCTAGAAT        This study

Plasmid Replicon Typing {#S2.SS6}
-----------------------

Plasmid DNA was isolated from *E. coli* using a SanPrep Column Plasmid Mini-Preps Kit plasmid isolation system (Sangon Biotech, Shanghai, China) and stored at −20°C, according to the manufacturer's instructions. Plasmid replicon typing of *E. coli* was performed using a multiplex PCR-based method with 18 pairs of primers, as described previously ([@B6]). The typing results were obtained by agarose gel electrophoresis and verified by sequencing.

Analysis of Genetic Environment of Beta-Lactamase Genes {#S2.SS7}
-------------------------------------------------------

The genetic environment of the beta-lactamase genes was detected by long PCR using LA-Taq PCR solution (TaKaRa) according to the manufacturer's instructions. Primers to detect the genetic environment surrounding the beta-lactamase genes were designed according to the sequences corresponding to the GenBank Accession numbers listed in [Figure 1](#F1){ref-type="fig"}, using Vector NTI advance 11.0 software. The template was initially denatured at 94°C for 4 min, followed by 35 cycles of 94°C for 40 s, 55°C for 1 min, and 72°C for 5 min, with a final extension at 72°C for 10 min. The PCR products were verified by agarose gel electrophoresis and sequencing, and all sequencing results were aligned using the BLAST program. The primers are listed in [Table 1](#T1){ref-type="table"}.

![Schematic diagram of the genetic environment surrounding the beta-lactamase genes. ^∗^GenBank Accession numbers. (Sequences of PCR products were analyzed with BLAST to identify target homologous sequences and their GenBank accession numbers; <https://blast.ncbi.nlm.nih.gov/Blast.cgi>).](fmicb-10-02175-g001){#F1}

Phylogenetic Grouping and Sequence Type (ST) Determination {#S2.SS8}
----------------------------------------------------------

The major phylogenetic group of each *E. coli* strain was determined by multiplex PCR, using the primers listed in [Table 1](#T1){ref-type="table"} ([@B9]). Multilocus sequence typing (MLST) was performed according to the Pasteur protocol^[2](#footnote2){ref-type="fn"}^. Eight conserved housekeeping genes were amplified by PCR using primer sets for *dinB*, *icdA*, *pabB*, *polB*, *putB*, *trpA*, *trpB*, and *uidA*, and sequenced ([Table 1](#T1){ref-type="table"}). Allele profiles and ST assays were performed according to the *E. coli* MLST website^[2](#footnote2){ref-type="fn"}^ protocol.

Results {#S3}
=======

Antimicrobial Susceptibility {#S3.SS1}
----------------------------

Fifty bloodstream-infection *E. coli* isolates were obtained from elderly patients (average age, 70.86 years, range 51--92 years; 30% men, 70% women). Most isolates came from the intensive care unit (76%, 38/50), and others from the hematology medical ward (14%, 7/50) and other wards (10%, 5/50). *In vitro* antimicrobial susceptibility testing showed that most isolates were sensitive to gentamicin (32%), trimethoprim/sulfamethoxazole (38%), chloramphenicol (46%), ciprofloxacin (48%), levofloxacin (50%), ampicillin (82%), aztreonam (36%), cefepime (54%), cefotaxime (54%), ceftazidime (24%), cefazolin (54%), ceftriaxone (21%), and cefoxitin (9%). Moreover, all the isolates were sensitive to imipenem, amikacin, tobramycin, and meropenem.

Genotypes of Beta-Lactamase Genes {#S3.SS2}
---------------------------------

Of the 50 strains, 33 were positive for the beta-lactamase genotype \[21 ESBL phenotypes/beta-lactamase genotype positive ([Table 2](#T2){ref-type="table"}); 12 beta-lactamase genotype positive/phenotype negative ([Table 3](#T3){ref-type="table"})\], Of these 33 strains, one (3%, 1/33) contained three beta lactamase genes, eight (24%, 8/33) contained two beta lactamase genes, and 24 (73%, 24/33) contained only one beta lactamase gene. Among the beta-lactamase-producing strains, 21 isolates were positive for *bla*~TEM~, one for *bla*~SHV~, one for *bla*~CIT,~ two for the *bla*~CTX--M--1~ group, 13 for the *bla*~CTX--M--9~ group, and five for the *bla*~OXA--1~ group. Nucleotide sequence analysis showed that 21 *bla*~TEM~-positive isolates carried *bla*~TEM--1~ and both *bla*~CTX--M--1~ group-positive isolates carried *bla*~CTX--M--55~. Of 13 *bla*~CTX--M--9~ group-positive isolates, one had *bla*~CTX--M--65~, three had *bla*~CTX--M--27~, and nine carried *bla*~CTX--M--14~. The only *bla*~SHV~ sequenced was *bla*~SHV--42~, the only *bla*~ADC~ sequenced was *bla*~ADC--162~, the only *bla*~CIT~ sequenced was *bla*~CMY--2~, and all 5 *bla*~OXA--1~ group-positive isolates carried *bla*~OXA--30~. Meanwhile, all 50 isolates were negative for *bla*~SME~, *bla*~PER~, *bla*~DHA,~ *bla*~ACC,~ *bla*~EBC,~ *bla*~CTX--M--2~ group, *bla*~CTX--M--8~ group, and *bla*~CTX--M--25~ group ([Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}).

###### 

ESBL-positive bloodstream-infection *Escherichia coli* resistance phenotypes and genotypes.

  **Strain**   **ESBL**   **MLST**   **PG**   **Plasmid replicon type**   **MIC**   ***bla* gene product**   **Transfer**                                                  
  ------------ ---------- ---------- -------- --------------------------- --------- ------------------------ -------------- ------ ------ ------ ------------------------- ----
  EC-2         \+         ST51       B2       FIA,FIB,FrepB               \>16      \>16                     \>32           16     \>16   ≤      OXA-30                    \+
  EC-4         \+         ST9        A        ND                          16        16                       \>32           ≤1     \>16   16     OXA-30,CTX-M-65           \+
  EC-6         \+         ST45       D        FIA,FIB,FrepB,N,K           ≤2        \>16                     16             ≤1     \>16   ≤8     CTX-M-14                  \+
  EC-7         \+         ST48       B2       FIA,FIB,I1,K                \>16      \>16                     \>32           8      \>16   ≤8     TEM-1,CTX-M-55,CTX-M-14   \+
  EC-9         \+         ST95       B2       FIC,K                       8         \>16                     \>32           \>16   \>16   \>32   CMY-2,CTX-M-14            \+
  EC-13        \+         ST2        B2       FIA,FIB,FrepB,N,K           \>16      \>16                     \>32           \>16   \>16   ≤8     TEM-1                     \+
  EC-20        \+         ST730      B2       FrepB,K                     4         \>16                     \>32           ≤1     \>16   ≤8     CTX-M-14                  \+
  EC-24        \+         ST131      B2       FIB,FrepB,K                 8         \>16                     \>32           4      \>16   16     CTX-M-27                  \+
  EC-25        \+         ST48       B1       FIB,FrepB,K                 \>16      \>16                     \>32           \>16   \>16   ≤8     TEM-1                     \+
  EC-27        \+         ST131      B2       FIA,FIB,FrepB,N,K           \>16      \>16                     \>32           \>16   \>16   ≤8     TEM-1,CTX-M-55            \+
  EC-29        \+         ST31       B2       FIA,FIB,FrepB,N,K           ≤2        16                       \>32           ≤1     \>16   16     TEM-1                     \+
  EC-31        \+         ST9        D        FIB,FrepB,K                 ≤2        16                       \>32           ≤1     \>16   ≤8     OXA-30,CTX-M-14           \+
  EC-32        \+         ST51       D        I1,Y,K                      \>16      \>16                     \>32           16     \>16   ≤8     TEM-1                     \+
  EC-36        \+         ST131      B2       FIA,FIB,FrepB,N,K           \>16      \>16                     \>32           \>16   \>16   ≤8     CTX-M-27                  \+
  EC-37        \+         ST2        B2       FIB,FrepB,K,P               4         \>16                     \>32           ≤1     \>16   ≤8     TEM-1                     \+
  EC-38        \+         ST95       A        FIC                         8         \>16                     \>32           2      \>16   \>32   ADC-162                   \+
  EC-39        \+         ST681      B2       FIA,FIB,FrepB               \>16      \>16                     \>32           2      \>16   ≤8     TEM-1,CTX-M-14            \+
  EC-41        \+         ST131      B2       FIB,FrepB,K                 16        \>16                     \>32           4      \>16   16     TEM-1,CTX-M-27            \+
  EC-43        \+         ST48       D        K,B                         8         \>\>16                   \>32           2      \>16   16     TEM-1,CTX-M-14            \+
  EC-48        \+         ST9        B2       FIA,FIB                     \>16      \>16                     \>32           \>16   \>16   16     TEM-1                     \+
  EC-50        \+         ST9        D        FIB,FrepB,K                 ≤2        \>16                     \>32           ≤1     \>16   16     OXA-30,CTX-M-14           \+

PG, phylogenetic group; MIC, minimum inhibitory concentration.

###### 

ESBL-negative bloodstream-infection *Escherichia coli* resistance phenotypes and genotypes.

  **Strain**   **ESBL**   **MLST**   **PG**   **Plasmid replicon type**   **MIC**   ***bla* gene product**   **Transfer**                           
  ------------ ---------- ---------- -------- --------------------------- --------- ------------------------ -------------- ---- ---- ---- -------- ----
  EC-1         −          ST51       B2       FIA,FIB,K                   ≤2        ≤2                       ≤1             ≤1   ≤4   ≤8   TEM-1    \+
  EC-3         −          ST2        B2       ND                          ≤2        ≤2                       ≤1             ≤1   ≤4   ≤8   TEM-1    \+
  EC-16        −          ST1        B1       FrepB,K                     ≤2        ≤2                       ≤1             ≤1   ≤4   ≤8   TEM-1    \+
  EC-18        −          ST51       B2       K                           ≤2        ≤2                       ≤1             ≤1   ≤4   ≤8   TEM-1    \+
  EC-21        −          ST2        A        FrepB,K                     ≤2        ≤2                       ≤1             ≤1   ≤4   ≤8   TEM-1    \+
  EC-23        −          ST8        B2       FIB,FrepB,K                 ≤2        ≤2                       ≤1             ≤1   ≤4   ≤8   TEM-1    \+
  EC-26        −          ST2        B2       K                           ≤2        ≤2                       ≤1             ≤1   ≤4   ≤8   TEM-1    \+
  EC-28        −          ST117      A        FIB,FrepB,K                 ≤2        ≤2                       ≤1             ≤1   ≤4   ≤8   TEM-1    \+
  EC-33        −          ST45       B2       FIB,FrepB,K                 ≤2        ≤2                       ≤1             ≤1   ≤4   ≤8   TEM-1    \+
  EC-35        −          ST730      A        ND                          ≤2        ≤2                       ≤1             ≤1   ≤4   ≤8   OXA-30   −
  EC-42        −          ST95       A        ND                          ≤2        ≤2                       ≤1             ≤1   ≤4   ≤8   SHV-42   \+
  EC-49        −          ST51       B1       K                           ≤2        ≤2                       ≤1             ≤1   ≤4   ≤8   TEM-1    \+

PG, phylogenetic group; MIC, minimum inhibitory concentration.

Conjugation Experiments {#S3.SS3}
-----------------------

All 50 *E. coli* isolates were tested by conjugation and 39 strains were successfully transferred. Thirty-two of the 33 strains carrying beta-lactamase genes were successfully conjugated, but EC-35 was not successfully conjugated. Cefotaxime- and ceftazidime-resistance phenotypes were simultaneously transferred to sodium azide-resistant *E. coli* J53 recipients by conjugation in beta-lactamase-positive *E. coli* isolates, respectively.

The conjugate was detected by amplifying the beta lactamase gene primer and the results showed that most of the beta lactamase genes were transferred. However, four OXA-1-group (EC-4,EC-31,EC-35,EC-48), three TEM-group (EC-7,EC-32-EC-49), and four CTX-M-9-group (EC-4,EC-7, EC-27,EC-41) genes did not transfer and were not amplified in the corresponding transconjugants. Resistance to non-beta-lactamase antimicrobials was also co-transferred in some cases, in addition to the transfer of extended-spectrum cephalosporin resistance ([@B8]). The characteristics of the *E. coli* J53 transconjugants carrying beta-lactamase genes are shown in [Table 4](#T4){ref-type="table"}.

###### 

Genotypes and drug-resistance phenotypes of bloodstream-infection *Escherichia coli* conjugates.

  **Transconjugant**   **Donor strain**   **Plasmid replicon type**   ***bla* gene product**   **Not detected genotype**   **ESBL**   **Resistance cotransferred**
  -------------------- ------------------ --------------------------- ------------------------ --------------------------- ---------- -------------------------------------------
  J-EC-1               EC-1               FIA                         TEM-1                                                           AMP^R^
  J-EC-2               EC-2               FrepB                       OXA-30                                               \+         ATM^R^,FEP^R^,CTX^R^,CZO^R^,CTX^R^
  J-EC-3               EC-3               ND                          TEM-1                                                           AMP^R^
  J-EC-4               EC-4               ND                                                   OXA-30, CTX-M-55            NT         AMP^R^
  J-EC-6               EC-6               K                           CTX-M-14                                             NT         
  J-EC-7               EC-7               K                           CTX-M-14                 CTX-M-55, TEM-1             \+         ATM^R^,FEP^R^,CTX^R^,CZO^R^,CRO^R^
  J-EC-9               EC-9               FIC                         CMY-2,CTX-M-14                                       \+         FEP^R^,CTX^R^,CAZ^R^,CZO^R^,CRO^R^,FOX^R^
  J-EC-13              EC-13              FrepB                       TEM-1                                                \+         ATM^R^,FEP^R^,CTX^R^,CAZ^R^,CZO^R^,CRO^R^
  J-EC-16              EC-16              ND                          TEM-1                                                           AMP^R^
  J-EC-18              EC-18              ND                          TEM-1                                                           AMP^R^
  J-EC-20              EC-20              FrepB                       CTX-M-14                                             \+         FEP^R^,CTX^R^,CZO^R^
  J-EC-21              EC-21              ND                          TEM-1                                                           AMP^R^
  J-EC-23              EC-23              ND                          TEM-1                                                           AMP^R^
  J-EC-24              EC-24              K                           CTX-M-27                                             NT         
  J-EC-25              EC-25              K                           TEM-1                                                NT         AMP^R^
  J-EC-26              EC-26              ND                          TEM-1                                                           
  J-EC-27              EC-27              FrepB                       TEM-1                    CTX-M-55                    \+         ATM^R^,FEP^R^,CTX^R^,CAZ^R^,CZO^R^,CRO^R^
  J-EC-28              EC-28              ND                          TEM-1                                                           AMP^R^
  J-EC-29              EC-29              FrepB                       TEM-1                                                NT         
  J-EC-31              EC-31              K                           CTX-M-14                 OXA-30                      NT         
  J-EC-32              EC-32              I1                                                   TEM-1                       NT         
  J-EC-33              EC-33              ND                          TEM-1                                                           
  J-EC-36              EC-36              N                           CTX-M-27                                             NT         
  J-EC-37              EC-37              K                           TEM-1                                                \+         FEP^R^,CTX^R^
  J-EC-38              EC-38              FIC                         ADC-162                                                         FEP^R^,CTX^R^,CAZ^R^,CZO^R^,CRO^R^,FOX^R^
  J-EC-39              EC-39              K                           TEM-1,CTX-M-14                                       \+         ATM^R^,FEP^R^,CTX^R^
  J-EC-41              EC-41              FrepB                       TEM-1                    CTX-M-27                    NT         AMP^R^
  J-EC-42              EC-42              ND                          SHV-42                                                          AMP^R^
  J-EC-43              EC-43              FrepB                       TEM-1,CTX-M-14                                       \+         FEP^R^,CTX^R^
  J-EC-48              EC-48              ND                          TEM-1                                                NT         
  J-EC-50              EC-50              K                           CTX-M-14                 OXA-30                      \+         FEP^R^,CTX^R^,CZO^R^
  J-EC-49              EC-49              ND                                                   TEM-1                                  AMP^R^

EC-35 had no transconjugants. ND, Not detected; NT, not transferred, donor strain ESBL phenotype positive but conjugant strain ESBL phenotype negative.

Plasmid Analysis {#S3.SS4}
----------------

Replicon-typing data for the clinical isolates carrying beta-lactamase genes ([Table 2](#T2){ref-type="table"}) revealed 10 different replicon types. Among these, two or more plasmid replicon types were detected simultaneously in the 19/21 strain, no plasmid replicon type was detected in the EC-4 strain, and only one plasmid replicon (IncFIC) was carried in the EC-38 strain. The IncF plasmid replicon type was the most common replicon among both types of isolates. Among the ESBL-phenotype-negative strains, plasmid replicon types were not detected in three strains, and the remaining nine strains included only four plasmid replicon types, but all contained IncK plasmid replicons ([Table 3](#T3){ref-type="table"}).

Plasmid replicon analysis was carried out in the 32 strains with beta-lactamase genes and successful conjugation. Interestingly, no plasmid replicons were detected in 12 transconjugants, and the other 20 transconjugants carried only one plasmid. A total of three plasmid replicon types were detected: IncF (9/19), IncK (9/19), and IncN (1/19) ([Table 4](#T4){ref-type="table"}). Nine strains were negative for both ESBL genotypes and phenotypes, with no conjugation result and no detection of any plasmid replicon type ([Table 5](#T5){ref-type="table"}).

###### 

ESB-genotype-negative bloodstream-infection *Escherichia coli* resistance phenotypes and characterization of transconjugants.

  **Strain**   **MLST**   **PG**   **PRT**          **ESBL**   **MIC**   **Transfer**   **Transconjugants**                                                                       
  ------------ ---------- -------- ---------------- ---------- --------- -------------- --------------------- ------ ------ ---- ---- -------------------------------------- ---- -------
  EC-5         ST730      B2       ND               −          ≤2        ≤2             ≤1                    ≤1     ≤4     ≤8   −                                                
  EC-8         ST1        B2       ND               \+         \>16      \>16           \>32                  \>16   \>16   ≤8   \+   ATM^R^,FEP^R^, CTX^R^,CAZ^R^, CZO^R^   \+   ND
  EC-10        ST31       B2       FrepB,K          \+         \>16      \>16           \>32                  \>16   \>16   16   \+   ATM^R^,CTX^R^, CZO^R^                  NT   FrepB
  EC-11        ST681      B2       ND               \+         \>16      ≤8             ≤2                    4      ≤8     ≤8   −                                                
  EC-12        ST51       B1       ND               −          ≤2        ≤2             ≤1                    ≤1     ≤4     ≤8   −                                                
  EC-14        ST51       B2       FrepB,K          \+         \>16      \>16           \>32                  8      \>16   ≤8   \+   CZO^R^                                 \+   FrepB
  EC-15        ST117      B2       ND               −          ≤8        ≤8             ≤2                    ≤1     ≤8     ≤8   −                                                
  EC-17        ST45       B1       ND               −          ≤2        ≤2             ≤1                    ≤1     ≤4     ≤8   −                                                
  EC-19        ST48       B2       ND               −          ≤2        ≤2             ≤1                    ≤1     ≤4     ≤8   −                                                
  EC-22        ST2        A        ND               −          ≤2        ≤2             ≤1                    ≤1     ≤4     ≤8   −                                                
  EC-30        ST681      B1       ND               −          ≤2        ≤2             ≤1                    ≤1     ≤4     ≤8   −                                                
  EC-34        ST2        D        ND               −          ≤8        ≤8             ≤2                    ≤1     ≤8     ≤8   −                                                
  EC-40        ST117      D        FIB,FrepB,I1,K   \+         \>16      16             \>32                  \>16   \>16   ≤8   \+   CZO^R^                                 \+   FrepB
  EC-44        ST2        D        FIB,FrepB,K      \+         \>16      \>16           \>32                  \>16   \>16   ≤8   \+   ATM^R^,FEP^R^, CTX^R^,CZO^R^           \+   FrepB
  EC-45        ST2        B2       FIA,FIB,K        \+         16        \>16           \>32                  4      \>16   ≤8   \+   −                                      \+   ND
  EC-46        ST2        D        FrepB,K          −          ≤2        ≤2             ≤1                    ≤1     ≤4     ≤8   \+   −                                           FrepB
  EC-47        ST45       B2       ND               −          ≤2        ≤2             ≤1                    ≤1     ≤4     ≤8   −                                                

PG, phylogenetic group; PRT, plasmid replicon type; MIC, minimum inhibitory concentration.

Genetic Environment of Beta-Lactamase Genes {#S3.SS5}
-------------------------------------------

The genetic environment surrounding the beta-lactamase genes was verified. Overlapping PCR showed that all *bla*~CTX--M~ groups were IS*Ecp1* upstream and *orf477* or IS903 downstream. Both *bla*~TEM--1~ and *bla*~OXA--30~ were located between two transposes and *bla*~ADC--162~ was located between IS*Aba*1 and *tnpA*. Unexpectedly, the genetic environment surrounding EC-9 *E. coli* beta-lactamase genes was relatively unique; *bla*~CTX--M--14~ combined with *bla*~CMY--2~ through an insertion sequence (IS903), to constitute a composite structure of IS*Ecp1*-*bla*~CTX--M--14~-IS*903-bla*~CMY--2~-*blc*-*sug*E ([Figure 1](#F1){ref-type="fig"}).

Phylogenetic Group and ST Designation {#S3.SS6}
-------------------------------------

Phylogenetic analysis of *E. coli* isolates carrying beta-lactamase genes showed that 24 belonged to virulent groups B2 (*n* = 19) and D (*n* = 5), and nine to non-toxic groups B1 (*n* = 3) and A (*n* = 6). Similarly, analysis of *E. coli* isolates with non-beta-lactamase genes showed that 13 belonged to virulent groups B2 (*n* = 9) and D (*n* = 4), and four belonged to non-toxic groups B1 (*n* = 3) and A (*n* = 1).

MLST analysis identified 12 unique STs among the 50 *E. coli* isolates ([Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}, [5](#T5){ref-type="table"}): ST1 (*n* = 2), ST2 (*n* = 10), ST9 (*n* = 5), ST31 (*n* = 2), ST45 (*n* = 4), ST48 (*n* = 4), ST51 (*n* = 6), ST95 (*n* = 3), ST117 (*n* = 4), ST131 (*n* = 4), ST681 (*n* = 3), and ST730 (*n* = 3) strains.

Discussion {#S4}
==========

In the present study, we characterized the ESBL and AmpC phenotypes and genotypes of beta-lactamase-producing *E. coli* blood isolates from patients in China from 2014 to 2018. These results provide the first extensive molecular report of plasmid-mediated ESBL and AmpC beta-lactamase-producing *E. coli* strains isolated from the bloodstream in elderly patients. Of the 50 *E. coli* isolates studied, 28 were positive for ESBL phenotypes, 33 were positive for beta-lactamase genes, 21 strains were positive for both, and 10 were negative for both. Thirteen (61.9%) strains had *bla*~CTX--M~-type ESBL genes and two (9.5%) produced *ampC* genes. *bla*~CTX--M~-type genes were more common than *bla*~OXA~ and *bla*~SHV~, and *ampC* genes (*bla*~ADC~ and *bla*~CMY~) were observed sporadically. A previous study reported that the *bla*~TEM~ and *bla*~SHV~ genes were the most prevalent while the detection frequency of the CTX-M group was low among *E. coli* isolated from China ([@B19]), however, the current study found a higher prevalence and variety of *bla*~CTX--M~ genes than previously reported ([@B24]; [@B30]). The results of our study suggest that previous studies may have underestimated the frequency of *bla*~CTX--M~ gene transport in *Escherichia coli* samples isolated from blood, which may be related to increased selective pressure of cephalosporins in China.

The 50 *E. coli* isolates in the current study carried a variety of *bla*~CTX--M~ genes (*bla*~CTX--M--14~, 8/40; *bla*~CTX--M--27~, 3/40; *bla*~CTX--M--55~, 2/40; *bla*~CTX--M--65~, 1/40), and some also contained *bla*~TEM--1~ (21/40). Although these *bla*~CTX--M~ variants have previously been reported in *E. coli* strains isolated in many countries ([@B16]), few studies have detected the *ampC* gene in bloodstream-infection *E. coli* strains in China ([@B19]), and no previous studies have isolated *E. coli* from blood samples from elderly patients. In particular, we detected and confirmed a case of the *ampC* gene *bla*~ADC--162~. Related studies to date have only detected the *ampC* gene *bla*~CMY--2~ in clinical bloodstream infections of *Escherichia coli* in Europe, though genome-wide sequencing confirmed that certain strains of chicken carry *bla*~CMY--2~ with high homology ([@B18]; [@B12]; [@B23]). To the best of our knowledge, the current study provides the first evidence for *bla*~ADC--162~ in *Escherichia coli* strains isolated from clinical samples from patients bloodstream infections. Overall, our results indicated that the diversity of ESBL and/or *ampC* genes in *E. coli* strains is increasing, constituting a potential public health problem.

Among the beta-lactamase-genotype-positive strains, most beta-lactamase genes could be transferred to the recipient *E. coli* J53 strain by conjugation. Interestingly, 32 of the 33 beta-lactamase-genotype-positive strains were also carried conjugant plasmids, while EC-35 failed the conjugation test. EC-35 carried the *bla*~OXA--30~ gene, but no plasmid replicon was detected. Additional plasmid extraction experiments indicated that EC-35 carries a plasmid of approximately 15 kb in length, and the plasmid DNA amplified was positive for *bla*~OXA--30~ gene. EC-35 was shown to transmit the *bla*~OXA--30~ gene through a plasmid, consistent with previous reports ([@B5]). Eight of the remaining 32 conjugant strains partially or totally lost the beta-lactamase gene. No plasmid replicon was detected in J-EC-4 or J-EC-49, and the beta-lactamase gene was lost completely, and J-EC-7, J-EC-31, and J-EC-50 carried *bla*~CTX--M--14~, while the other beta-lactamase genes were lost. All the plasmid replicons were IncK and other plasmid replicons were lost, suggesting that *bla*~CTX--M--14~ can be transmitted by the IncK plasmid in bloodstream-infection *E. coli*. Previous reports indicated that *bla*~CTX--M--14~ was mainly related to the IncK plasmid in Spain and Britain ([@B5]). However, although both J-EC-6 and J-EC-31 had *bla*~CTX--M--14~ mediated by the IncK plasmid, the ESBL phenotype of the conjugant strains was lost. The genetic environment around their donor strains was △IS*Ecp*1 (regionY-42 bp) -- *bla*~CTX--M--14~-*orf*477. A 42 bp region with an identical sequence (Y sequence) was found upstream of the start codon of the beta-lactamase gene ([@B13]). Regarding J-EC-6 and J-EC-31, amplification of the primer pair (IS*Ecp*1-F and CTX-M-9-R) failed when identical primers were used to validate the genetic environment around *bla*~CTX--M--14~. Reverse PCR primers (M9R-F and M9R-R) were designed according to CTX-M-9, and sequencing and analysis of the reverse PCR amplification products revealed five and three base mutations in the△IS*Ecp*1 promoter regions of J-EC-6 and J-EC-31, respectively. This may have been due to an increase in the truncated length of IS*Ecp*1, resulting in the loss of promoters in the primer regions and abnormal expression of *bla*~CTX--M--14~.

In the present study, only EC-9 and EC-38 strains, with *bla*~CMY--2~ and *bla*~ADC--162~, respectively, were resistant to fosfomycin. EC-9 carried FIC and K plasmid replicates, and EC-38 carried FIC plasmid replicates. Both strains were ST95 but belonged to different developmental groups, B2 and A, respectively. The genetic environments around *bla*~CMY--2~ and *bla*~ADC--162~ were IS*Ecp*1 (regionY-42bp) -- *bla*~CTX--M--14~-IS903-*bla*~CMY--2~-*blc*-*sug*E and IS*Aba*1-*bla*~ADC--162~-*tnp*A, respectively. IS903 was inserted between two beta-lactamase genes in EC-9 to form a relatively complex tandem structure. Overlapping PCR demonstrated that IS*Ecp*1 (regionY-42bp)-*bla*~CTX--M--14~-IS903-*bla*~CMY--2~-*blc*-*sug*E could be completely transferred by conjugation. IS*Aba*1 in IS*Aba1*-*bla*~ADC--162~-*tnp*A is a specific insertion sequence found in *Acinetobacter baumannii*, which can mediate the transfer of drug-resistance genes. The current study provides the first evidence for the existence of the same IS*Aba*1-*bla*~ADC--162~-*tnp*A insertion sequence in *E. coli*, suggesting that IS*Aba*1 can be transmitted between *E. coli* and *A. baumannii* as a mobile genetic structural element.

Interestingly, *bla*~CMY--2~ and *bla*~ADC--162~ were successfully detected in J-EC-9 and J-EC-38, respectively, and both carried only FIC plasmid replicons, indicating that *bla*~CMY--2~ and *bla*~ADC--162~ were both transported by the IncF plasmid. Although only one IncF plasmid-mediated *bla*~CMY--2~ and one *bla*~ADC--162~-positive strain were detected in this study and no evidence of a cloning epidemic was found, the results suggested the need to remain highly vigilant. The IncF plasmid is known to contain three basic replicates: RepFIA, RepFIB, and RepFIC. The IncF plasmid is a narrow host plasmid with a specific region encoding multidrug-resistance genes. It is only prevalent in Enterobacteriaceae bacteria and can be used as a cloning agent ([@B29]). Multidrug resistance of the IncF plasmid is closely related to its mobile elements, including the insertion sequence, integron, and transposon, allowing it to capture or recombine resistance genes ([@B22]; [@B27]; [@B29]). It is therefore easy to conjugate and transfer, resulting in the dissemination of *bla*~CMY--2~ and *bla*~ADC--162~ clones, with potentially adverse consequences. To the best of our knowledge, this is the first report of IncF-plasmid-mediated *bla*~CMY--2~ and *bla*~ADC--162~ in bloodstream-infection *E. coli*, indicating the need to be vigilant.

The current results demonstrated that the horizontal transmission of beta-lactamase genes in bloodstream *E. coli* strains is mainly mediated by IncF and IncK plasmids. Despite the differences in plasmid skeleton and variety, few replicons were detected in bloodstream infection *E. coli*, and the conjugates carried only one type of replicon at most. In addition, the plasmids and genetic environment of the *bla*~CTX--M~ group play an important role in regulating the expression, transfer, and transmission of resistance genes. Detection of IS*Ecp*1 upstream of *bla*~CTX--M~, *bla*~CMY--2~, and *bla*~CMY--M~ genes with different plasmids showed that IS*Ecp*1 plays an important role in capturing, expressing, and continuously mobilizing *bla*~CTX--M~ group and *bla*~CMY--2~ genes. An IS*Ecp*1 insertion sequence upstream of the gene could result in high levels of expression of *bla*~CTX--M~ resistance genes and carry these resistance genes between chromosomes and plasmids for transfer, leading to spreading among different strains. Inserted sequences such as IS26, IS903, and *orf*477 are also frequently associated with b*la*~CTX--M~ resistance genes. These mobile genetic elements can be distributed randomly upstream and downstream of *bla*~CTX--M~ resistance genes, forming different genomic components in different *bla*~CTX--M~ resistance genes, acting on drug-resistance genes either together or separately, regulating their expression, and mediating their transmission.

Conclusion {#S5}
==========

To the best of our knowledge, this study provides the first molecular characterization of beta-lactamase genes from bloodstream isolates of *E. coli* from elderly patients. Beta-lactamase genes, especially *bla*~TEM--1~, *bla*~CTX--M--14~, *bla*~OXA--30~, *bla*~CTX--M--27~, *bla*~CTX--M--55~, and *bla*~CTX--M--65~, were widely prevalent in bloodstream-infection *E. coli* from these patients. Interestingly, *bla*~CMY--2~ and *bla*~ADC--162~ were both transported by IncF plasmids, which are prone to conjugation, indicating the potential for outbreak epidemics related to these genotypes of bloodstream-infection *E. coli*.
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